Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-05-26
1997-12-09
Ulm, John
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 44, 530350, 536 231, 536 235, 424 854, 424 855, 435 71, 435 691, 4352523, 4353201, A61K 3820
Patent
active
056960794
ABSTRACT:
A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by delivering a genetically engineered retrovital vector directly to the patient.
REFERENCES:
patent: 4863730 (1989-09-01), Karpas
patent: 4868157 (1989-09-01), Durette
patent: 5026687 (1991-06-01), Yarchoan et al.
patent: 5419900 (1995-05-01), Lane et al.
Piscitelli et al. (1994) Abstr. 34th. ICAAC 34:83.
Kovacs et al. (1993a) IXth Int. Conf. on AIDS 639P.
Kovacs et al. (1993b) Abstr. 33rd. ICAAC 33:328.
Smith (1988) Science 240:1165-1176.
Lane et al. (1985) Ann. Int. Med. 103:714-718.
Kovacs et al. (1995) N. Engl. J. Med. 332:567-575.
P.C. Kohler et al., "Enhanced In vivo Generation of LAK Cells by Repetitive Administration of IL-2, a Phase 1 Clinical Study", Immunology and Cytokines, Proc. of ASCO, vol. 6, Mar. 1987, 980.
Teppler et al., "Efficacy of Low Doses of the Polyethylene Glycol Derivative of Interleukin-2 in Modulating the Immune Response of Patients with Human Immunodeficiency Virus Type 1 Infection", JID, pp. 291-96 (1993).
R. Wood et al., "Safety and Efficacy of Polyethylene Glycol-Modified Interleukin-2 and Zidovudine in Human Immunodeficiency Virus Type 1 Infection: A Phase I/II Study", JID, pp. 519-24 (1993).
S. Kanwowska et al., "Passive Immunization for the Treatment and Prevention of HIV Infection", Biotechnology Therapeutics, 2(1-2), 31-48 (1991).
H. Teppler et al., J. Infect. Dis. 167:291-298 (1993).
H. Teppler et al., J. Exp. Med., 177:483-492 (1993).
J. National Cancer Institute, 85(8): 622-632 (1993).
M. Roberts et al., "Targeting of Human Immunodeficiency Virus-Infected Cells by CD8.sup.+ T Lymphocytes Armed With Universal T-Cell Receptors", Blood, vol. 84, No. 9, 1994, pp. 2878-2889.
Lane et al., J. Biol. Response Mos., 3: 512-516 (1984).
Stein et al., J. Infect. Dis., 165:352-363 (1993).
Schwartz et al., J. Acquir. Immune Defic. Syndr., 4(1): 11-23, (1991) (abstract only provided).
Schwartz et al., Biotherapy, 2:119-136 (1990).
Oyaizu et al., PNAS, 87: 2379-2383 (1990).
Matory et al., Journal of Biological Response Modifiers, 4:377-390 (1985).
A.A. Fauser, J. of Cellular Biochemistry, 45: 353-358 (1991).
Geszyme Catalog, Cytokine Research Products, 1991, pp. 19-20.
West, "Lymphokine-Activated Killer Lymphocytes: Biotherapeutic Clinical Trials", Imm. Ser., 48:79-92 (1989).
J. Boyd et al., "B Cell Responses to HIV and the Development of Human Monoclonal Antibodies", Clin. Exp. Immunol., 88: 189-202 (1992).
M. Reddy et al., "Di8fferential Effects of Interferon-.alpha..sub.2 and Interleukin-2 on Natural Killer Cell Activity in Patients with Acquired Immune Deficiency Syndrome", J. of Biol. Response Modifiers, pp. 379-386 (1984).
M. Cheever et al., "Interleukin 2 Administered In vivo Induses the Growth of Cultured T Cells In vivo", Journal of Immunology, vol. 132, No. 5, 1994, pp. 2259-2265.
Fauci Anthony S.
Kovacs Joseph A.
Lane H. Clifford
Sorensen Kenneth A.
The United States of America as represented by the Department of
Ulm John
LandOfFree
Immunologic enhancement with intermittent interleukin-2 therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunologic enhancement with intermittent interleukin-2 therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunologic enhancement with intermittent interleukin-2 therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1607661